Navigation Links
Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
Date:12/3/2010

EAST HANOVER, N.J., Dec. 3, 2010 /PRNewswire/ -- A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa® (zoledronic acid) significantly improved overall survival (OS) and progression-free survival (PFS) in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs) (1,2).

The published results are from Medical Research Council (MRC) Myeloma IX, a large, randomized, Phase III clinical trial of nearly 2,000 patients with multiple myeloma (1). These results were initially reported at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, in June 2010.

At a median follow-up of 3.7 years, Zometa significantly reduced the risk for death by 16% (hazard ratio [HR] 0.842; 95% confidence interval [CI] 0.74-0.96; P=0.0118) and the relative risk for PFS events by 12% (HR 0.88; 0.80-0.98; P=0.0179) compared with oral clodronate. In addition to demonstrating superiority to clodronate on survival endpoints, Zometa was significantly superior to clodronate in the prevention of SREs associated with multiple myeloma, regardless of SRE history at baseline (1).

More than 750,000 cases of multiple myeloma are diagnosed each year worldwide, with a median overall survival of three to five years (3). Nearly 95% of advanced stage multiple myeloma patients have bone disease and half of them will experience SREs (e.g., pathologic fractures, radiation or surgery to bone, spinal cord compression) if not treated (4,5).

"As a hematologist who treats patients with multiple myeloma, the survival benefit demonstrated by Zometa in this study is very encouraging," said Professor Gareth Morgan, Head of Haemato-oncology at The Royal Marsden and The Institute of Cancer Research, UK and one of the study's lead in
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
2. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
3. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
4. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
5. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
6. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
7. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
8. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
10. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Does your doctor ... nearly 800 doctors have recommended marijuana to the over 112,000 ... 20. But the majority of the other roughly 20,300+ active ... know very little about it – even though a poll ... adults say they have tried it. ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... 2011 Cynosure, Inc. (Nasdaq: CYNO ), ... invasive and non-invasive aesthetic applications, today announced that two ... cellulite reduction have received key international regulatory clearances. ... License authorizing the sale in Canada of the company,s ...
... SANTA CLARA, Calif., March 15, 2011 NewCardio, Inc. (OTC Bulletin ... today that the Company expects to file its Form 10-K for ... management will conduct a conference call to provide a corporate update ... Corporate Update Conference Call When : 1:30 p.m. ...
Cached Medicine Technology:Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 2Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 3NewCardio to Conduct Corporate Update Conference Call on March 29, 2011 2
(Date:8/30/2014)... 2014: The first recommendations on the use of ... published today in new ESC Guidelines. The guidelines ... V. Konstantinides (Germany/Greece) and Professor Adam Torbicki (Poland). ... and management of acute pulmonary embolism" are published ... on the ESC Website. , Venous thromboembolism (VTE) ...
(Date:8/29/2014)... The Enchant Him review that was recently published by ... system that promises to teach ladies how to gain control ... who actually is a popular relationship expert and coach. ... advices out there, Carrie worked at this program with Nick ... is a simple to use step by step method. This ...
(Date:8/29/2014)... 29, 2014 The Fibroids Miracle review indicates ... naturally. The program promises fast and powerful results. It actually ... caused by fibroids in only 12 hours. The method promises ... The new system is based on a 3 step method ... its review that the program was in fact created by ...
(Date:8/29/2014)... Colorado (PRWEB) August 29, 2014 According to ... popular hardware detection tool at the moment, as it is ... the best hardware detection tool in the industry. , ... any customer hardware driver. The new program is highly effective ... devices to work perfectly. , Daily Gossip writes in ...
(Date:8/29/2014)... Cosmetic Town has devised a system ... its doctors. Cosmetic Town utilizes a validated referral ... in their field are chosen to present their procedure. ... direct link to potentially hundreds of recommended doctors in ... to communicate through the site’s community features and multimedia ...
Breaking Medicine News(10 mins):Health News:First recommendations on all new oral anticoagulants in pulmonary embolism published 2Health News:Enchant Him Review Reveals Unique Relationship Tips for Women 2Health News:Fibroids Miracle Review Exposes Amanda Leto’s 3-Step Holistic System 2Health News:Driver Robot Review Exposes Popular Hardware Detection Tool 2Health News:Cosmetic Town Now Advocates for the Rights of Cosmetic Patients Using Novel Approach 2
... resistant to targeted therapy drugs has revealed two previously ... March 23 Science Translational Medicine , investigators from ... how the cellular nature of some tumors actually changes ... can disappear after treatment is discontinued. The findings ...
... , WEDNESDAY, March 23 (HealthDay News) -- ... become resistant to targeted drug therapy. Researchers at ... from 37 patients with non-small cell lung cancer, the ... new genetic changes associated with resistance. They also ...
... study of its kind, urologists and biostatisticians at Henry Ford ... glands is safe over the long term, with a major ... published online this month by the journal European Urology, ... 87 percent of patients whose cancerous prostates were removed by ...
... , TUESDAY, March 22 (HealthDay News) -- Trauma injury patients ... weeknight are no more likely to die than those who ... The findings contrast with previous research that said patients with ... outcomes if they arrive at the hospital at night or ...
... every year there are reports of a young, apparently healthy athlete ... of Wes Leonard, a junior at Fennville High School, who died ... have parents and coaches wondering if enough is being done to ... to develop a better screening program to help prevent sudden cardiac ...
... at Virginia Commonwealth University Massey Cancer Center and VCU ... mechanism in gene regulation that contributes to the development ... (HCC). Currently, there is virtually no effective treatment for ... for therapeutic intervention. In the journal ...
Cached Medicine News:Health News:Mass. General study reveals how lung cancers evolve in response to targeted treatment 2Health News:Mass. General study reveals how lung cancers evolve in response to targeted treatment 3Health News:Lung Cancer Evolves With Treatment, Study Finds 2Health News:Long-term study: Robot-assisted prostate surgery is safe 2Health News:Trauma Patients Seem More Likely to Survive on Weekends 2Health News:Do all student athletes need heart screenings? 2Health News:Do all student athletes need heart screenings? 3Health News:Discovery in liver cancer cells provides new target for drugs 2
A kit will amplify and hybridize 100 samples. Kit components include: Primers, PCR Buffer, dNTPS, Taq Polymerase, Hybridization Solution, Quick-Light™ Buffer, 20 X SSC Concentrate, Lumi-Phos&re...
This ELISA test is used for the detection and semi-quantitation of lgG antibobies to proteinase 3(pr3) in human sera, as an aid to the diagnosis of wegener s granulomatosis....
The assay is an immunometric ('sandwich') EIA for the quantitative measurement of LH in human serum or plasma. LH in the sample is bound by 2 monoclonal anti-LH antibodies directed at different epito...
... II Direct to High Res SSP kits provide high ... tray. Locus specific typing on a single tray reduces ... Straight from genomic DNA to high resolution results, no ... typing with a single tray , Unique reaction pattern ...
Medicine Products: